Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as bimatoprost eye drops
bimatoprost eye · 1 trial · 2 indications
Change from Baseline in macroscopic conjunctival hyperemia (or visible eye redness). Macroscopic conjunctival hyperemia is graded by the investigator who compares the patient's visual appearance of eye redness to standard photographs using a 5-point scale (Scale 0 to +3: none, trace, mild, moderate, severe). The peak change is calculated for each eye by subtracting the largest score across the hourly measurements at baseline from the largest score across the hourly measurements at month 1. A positive number severity grade change from baseline indicated an increase in redness.
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | bimatoprost eye drops |
| 2 | PLACEBO_COMPARATOR | placebo |
| Name | Type | Description |
|---|---|---|
| bimatoprost eye drops | DRUG | 1 drop in each eye daily for 1 month |
| placebo | DRUG | 1 drop in each eye daily for 1 month |
Inclusion Criteria: * Chronic glaucoma or ocular hypertension * IOP controlled on Xalatan Exclusion Criteria: * Uncontrolled medical conditions * Known hypersensitivity to study medications
Top 5 of 7 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Glaukos Corp | GKOS | 6 | PHASE3 | Gen 2 Travoprost Intracameral, Travoprost |
| SpyGlass Pharma, Inc. | SGP | 5 | PHASE3 | Bimatoprost System, BIM-DRS |
| AbbVie, Inc. | ABBV | 2 | PHASE3 | AGN-193408 |
| Amneal Pharmaceuticals, Inc. Class A | AMRX | 1 | PHASE3 | Bimatoprost ophthalmic solution |
| Regeneron Pharmaceuticals, Inc. | REGN | 1 | PHASE1 | REGN22530 |
Bimatoprost eye is used to treat glaucoma and ocular hypertension, conditions in which pressure inside the eye is elevated. It is an ophthalmology small molecule developed by AbbVie Inc. (ticker ABBV). The clinical program has studied it in adults 18 years and older with glaucoma or ocular hypertension.
Bimatoprost eye targets PTGFR, the prostaglandin F receptor, and acts as an agonist at that receptor. This target class, prostaglandin F receptor agonism, is the mechanism studied in the glaucoma and ocular hypertension program run by AbbVie Inc. (ABBV).
Bimatoprost eye is developed by AbbVie Inc., which trades under the ticker ABBV. AbbVie is the company associated with the clinical development program for this ophthalmology small molecule in glaucoma and ocular hypertension.
Bimatoprost eye is in Phase 2 development for glaucoma and ocular hypertension. It is an investigational small molecule and is not described as approved. The Phase 2 program includes one completed trial, and no trials are currently listed as active.
Bimatoprost eye has been studied in trial NCT00538304, titled A Study of the Safety and Efficacy of Bimatoprost in Patients With Glaucoma or Ocular Hypertension. That Phase 2 trial was completed, enrolled 222 patients in the United States, and was randomized, double blind, and placebo controlled.
Yes, bimatoprost eye and bimatoprost eye drops refer to the same asset. Bimatoprost eye drops is an alternative name for this AbbVie Inc. (ABBV) ophthalmology small molecule being studied in glaucoma and ocular hypertension.